Clinical determinants of aspirin resistance in diabetes

Diabetes Research and Clinical Practice

Volumn 90, Issue 1, 2010, Pages

  Yassine, Hussein N ^a   Davis Gorman, Grace ^b   Stump, Craig S ^a,c   Thomson, Stephen S ^a,c   Peterson, Justin ^a   McDonagh, Paul F ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Aspirin Resistance; Diabetes; Insulin Resistance; Platelets; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN A1C;

ADULT; ARTICLE; BLOOD EXAMINATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PATIENT ASSESSMENT; PREDICTION; THROMBOCYTE AGGREGATION; URINALYSIS; WAIST CIRCUMFERENCE;

ALBUMINURIA; ASPIRIN; COHORT STUDIES; DIABETIC ANGIOPATHIES; DRUG RESISTANCE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOXANE B2; WAIST CIRCUMFERENCE;

EID: 77956192265     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.07.008     Document Type: Article

References (14)

1. Wang T.H., Bhatt D.L., Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006, 27(6):647-654.
2. Chen W.H., et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004, 43(6):1122-1126.
3. Chen W.H., et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007, 120(7):631-635.
4. DiChiara J., et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007, 56(12):3014-3019.
5. Eikelboom J.W., et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105(14):1650-1655.
6. Stern S.E., et al. Identification of individuals with insulin resistance using routine clinical measurements. Diabetes 2005, 54(2):333-339.
7. Winocour P.D., et al. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost 1992, 68(5):577-582.
8. Cipollone F., et al. Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000, 102(9):1007-1013.
9. Lordkipanidze M., et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007, 28(14):1702-1708.
10. Davi G., et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002, 288(16):2008-2014.
11. Tran H.A., et al. Aspirin resistance. Thromb Res 2007, 120(3):337-346.
12. Colwell J.A. Aspirin therapy in diabetes. Diabetes Care 2003, 26(Suppl. 1):S87-S88.
13. Belch J., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008, 337:a1840.
14. Ogawa H., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008, 300(18):2134-2141.